7622 The Effects of Fibroblast Growth Factor-21 Analogues in Patients with Metabolic Dysfunction Associated Steatohepatitis (MASH): A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bibliographic record
Abstract
Abstract Disclosure: J.C. Cardoso: None. R.Y. Ura Sudo: None. M.C. Souza: None. F.D. Pessôa: None. F.A. Moraes: None. N.M. Oliveira: None. F.A. Kelly: None. L.M. Lopes: None. P.G. Lima: None. M.S. Barros: None. F.F. Bandeira: None. Fibroblast growth factor 21 (FGF-21), has been proposed to improve liver histologic features, hepatic steatosis and markers of inflammation and fibrosis, thus emerging as a treatment avenue to metabolic dysfunction associated steatohepatitis (MASH). However, the potential treatment effects of FGF-21 analogues remain unclear. Therefore we aimed to perform a meta analysis exploring the effects on the liver of FGF-21 analogues when compared to placebo. We systematically searched different databases for randomized controlled trials (RCT): Pubmed, Web of Science, Cochrane - from inception to January 2024. Statistical analysis was performed in R software 4.3.1. A random-effects model was employed to compute mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI) for continuous and binary endpoints, respectively. A p-value of <0.05 was considered statistically significant. Heterogeneity was examined with the Cochran Q test, prediction interval and I² statistics. The results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement guideline. The protocol was registered in PROSPERO (CRD42023493083). A total of 12 RCTs with 1235 patients were included, of whom 852 (69%) were randomized to FGF-21 analogues therapy. The mean age was 54 years and the mean body mass index (Kg/m²) was 39.1. Over a mean follow-up time of 31.667 weeks, the analysis showed us that while the ≥ 50% reduction in hepatic fat fraction (HFF) (RR 6.53; 95% CI 3.13 to 13.63; p < 0.001; I² = 0%) and the fibrosis improvement in ≥1 stage without worsening of MASH (RR 1.77; 95% CI 1.12 to 2.79; P=0.0145; I² =29%) were significantly higher in patients treated with FGF-21 analogues compared with placebo, the higher MASH resolution without worsening of fibrosis (RR 2.48; 95% CI 0.87 to 7.08; P=0.090;I²=60%) in FGF-21 group wasn’t statistically significant. The FGF-21 group also presented significantly mean decreases in ELF score (MD -0.45; 95% CI -0.64 to -0.25; p < 0.001; I² =34%), liver stiffness (MD -2.10 KPa; 95% CI -3.53 to -0.68; p = 0.004; I²=94%), GGT (MD -16.33 U/L; 95% CI -29.92 to -2.75; p=0.018; I²=81%), ALP (MD -7.95 U/L; 95% CI -11.53 to -4.37; p<0.001; I²=0%), HFF (MD -40.26%; 95% CI -63.01 to -17.51; p < 0.001; I²=97%), ALT (MD -19.31%; 95% CI -28.84 to -9.77; p<0.001; I²=63%), AST (MD -19.32%; 95% CI -28.53 to -10.11; p<0.001; I² =59%), Pro-C3 (MD -13.65%; 95% CI -21.93 to -5.38; p=0.001; I²=81%). In conclusion, the use of FGF-21 analogues significantly improves liver histologic features, inflammation and fibrosis, however there were nonsignificant improvement in the composite outcome of MASH resolution without worsening of fibrosis. Presentation: 6/3/2024
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.013 | 0.025 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.021 | 0.035 |
| Bibliometrics | 0.007 | 0.008 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.003 | 0.002 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".